National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Chronic Myeloproliferative Disorders Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 08/01/2008



General Information About Chronic Myeloproliferative Disorders






Chronic Myelogenous Leukemia






Polycythemia Vera






Chronic Idiopathic Myelofibrosis






Essential Thrombocythemia






Chronic Neutrophilic Leukemia






Chronic Eosinophilic Leukemia






Stages of Chronic Myeloproliferative Disorders






Treatment Option Overview







Treatment Options for Chronic Myeloproliferative Disorders






To Learn More About Chronic Myeloproliferative Disorders






Get More Information From NCI






Changes to This Summary (08/01/2008)






About PDQ



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Treatment Options for Chronic Myeloproliferative Disorders

Chronic Myelogenous Leukemia
Polycythemia Vera
Chronic Idiopathic Myelofibrosis
Essential Thrombocythemia
Chronic Neutrophilic Leukemia
Chronic Eosinophilic Leukemia

A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.

Chronic Myelogenous Leukemia

See the PDQ summary on Chronic Myelogenous Leukemia Treatment for information.

Polycythemia Vera

The purpose of treatment for polycythemia vera is to reduce the number of extra blood cells. Treatment of polycythemia vera may include the following:

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with polycythemia vera.

Chronic Idiopathic Myelofibrosis

Treatment of chronic idiopathic myelofibrosis in patients without symptoms is usually watchful waiting.

Treatment of chronic idiopathic myelofibrosis in patients with symptoms may include the following:

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with chronic idiopathic myelofibrosis.

Essential Thrombocythemia

Treatment of essential thrombocythemia in patients younger than 60 years who have no symptoms and an acceptable platelet count is usually watchful waiting. Treatment of other patients may include the following:

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with essential thrombocythemia.

Chronic Neutrophilic Leukemia

Treatment of chronic neutrophilic leukemia may include the following:

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with chronic neutrophilic leukemia.

Chronic Eosinophilic Leukemia

Treatment of chronic eosinophilic leukemia may include the following:

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with chronic eosinophilic leukemia.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov